VANDA PHARMACEUTICALS INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
VANDA PHARMACEUTICALS INC. (VNDA) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $77.33 million for the 6-month period ending 2012-06-30, per its 10-Q filed 2012-08-03.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2012-08-03
- VANDA PHARMACEUTICALS INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2012-06-30 was $17.43M, a 62.04% decline year-over-year.
- VANDA PHARMACEUTICALS INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2012-03-31 was $59.90M, a 1.20% decline year-over-year.
- VANDA PHARMACEUTICALS INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2011-12-31 was $50.92M, a 128.85% increase year-over-year.
- VANDA PHARMACEUTICALS INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2011-09-30 was $68.70M, a 212.27% increase year-over-year.
- VANDA PHARMACEUTICALS INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2011 was $226.17M, a 383.79% increase from fiscal 2010.
- VANDA PHARMACEUTICALS INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2010 was $46.75M, a 152.70% increase from fiscal 2009.
- VANDA PHARMACEUTICALS INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2009 was $18.50M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2012-06-30 | $17.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $77.33M 10-Q · filed 2012-08-03 | $128.25M derived: sum of 3 quarters · filed 2012-08-03 | $196.95M derived: sum of 4 quarters · filed 2012-08-03 |
| 2012-03-31 | $59.90M 10-Q · filed 2012-05-09 | $110.82M derived: sum of 2 quarters · filed 2012-05-09 | $179.52M derived: sum of 3 quarters · filed 2012-05-09 | $225.44M derived: sum of 4 quarters · filed 2012-08-03 |
| 2011-12-31 | $50.92M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-09 | $119.62M derived: sum of 2 quarters · filed 2012-03-09 | $165.54M derived: sum of 3 quarters · filed 2012-08-03 | $226.17M 10-K · filed 2012-03-09 |
| 2011-09-30 | $68.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | $114.63M derived: sum of 2 quarters · filed 2012-08-03 | $175.25M 10-Q · filed 2011-11-07 | $197.50M derived: sum of 4 quarters · filed 2012-08-03 |
| 2011-06-30 | $45.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $106.55M 10-Q · filed 2012-08-03 | $128.80M derived: sum of 3 quarters · filed 2012-08-03 | $150.80M derived: sum of 4 quarters · filed 2012-08-03 |
| 2011-03-31 | $60.63M 10-Q · filed 2012-05-09 | $82.88M derived: sum of 2 quarters · filed 2012-05-09 | $104.88M derived: sum of 3 quarters · filed 2012-05-09 | |
| 2010-12-31 | $22.25M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-09 | $44.25M derived: sum of 2 quarters · filed 2012-03-09 | $46.75M 10-K · filed 2012-03-09 | |
| 2010-09-30 | $22.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | $24.50M 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | $2.50M 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | $18.50M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |